Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amitriptyline hydrochloride, quantity: 10 mg - tablet - excipient ingredients: magnesium stearate; colloidal anhydrous silica; hypromellose; microcrystalline cellulose; crospovidone; maize starch; purified talc; lactose monohydrate; brilliant blue fcf aluminium lake; titanium dioxide; macrogol 6000 - for the treatment of major depression. amitriptyline 50 mg tablets are indicated only for the maintenance treatment of major depression ,nocturnal enuresis where organic pathology has been excluded.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amitriptyline hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate; colloidal anhydrous silica; microcrystalline cellulose; disodium edetate; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; indigo carmine; sunset yellow fcf; quinoline yellow; macrogol 4000 - for the treatment of major depression. nocturnal enuresis where organic pathology has been excluded.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amitriptyline hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; colloidal anhydrous silica; lactose monohydrate; disodium edetate; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; purified talc; titanium dioxide; brilliant blue fcf; xanthan gum; lecithin - for the treatment of major depression. nocturnal enuresis where organic pathology has been excluded.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

discus dental australia pty ltd -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

discus dental australia pty ltd -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

discus dental australia pty ltd -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

discus dental australia pty ltd -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium chloride, quantity: 900 mg - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - for the restoration and maintenance of salt and extracellular fluid levels or as a vehicle for the administration of parenteral drugs.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium chloride, quantity: 450 mg - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - for the restoration and maintenance of salt and extracellular fluid levels or as a vehicle for the administration of parenteral drugs.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium bicarbonate, quantity: 8.4 g - injection, intravenous infusion - excipient ingredients: disodium edetate; water for injections - 1. metabolic acidosis in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis where a rapid increase in plasma total co2 content is crucial. treatment of metabolic acidosis should be concurrent with measures designed to control the cause of the acidosis. 2.urinary alkalinisation in the treatment of certain drug intoxications (ie barbiturates, salicylates, lithium, methyl alcohol) and in the haemolytic reactions requiring alkalinisation of the urine to diminish nephrotoxicity of blood pigments. urinary alkalinisation is also used in methotrexate therapy to prevent nephrotoxicity. 3.severe diarrhoea which is often accompanied by a significant loss of bicarbonate.